抗多重耐药革兰氏阴性菌抗生素研发管线：当前和未来的前景。
The antibiotic development pipeline for multidrug‐resistant gram‐negative bacilli: current and future landscapes.
机构信息
Talbot Advisors LLC, Wayne, Pennsylvania, USA.
出版信息
Infect Control Hosp Epidemiol. 2010 Nov;31 Suppl 1:S55-8. doi: 10.1086/655988.
DOI:10.1086/655988
PMID:20929372
Abstract
Development of antibiotics to treat infections caused by multidrug‐resistant gram‐negative bacilli has lagged significantly behind development of antibiotics to treat infections with gram‐positive pathogens. Although a few promising drugs have entered early clinical development, more must be done to preserve the utility of currently available antibiotics and to ensure a pipeline of efficacious, safe antibacterials.
摘要
治疗多重耐药革兰氏阴性杆菌感染的抗生素的发展明显滞后于治疗革兰氏阳性病原体感染的抗生素的发展。尽管有几种有前途的药物已经进入早期临床开发阶段，但仍需做更多的工作来保持现有抗生素的效用，并确保有有效的、安全的抗菌药物供应。
Zotero 插件